105 related articles for article (PubMed ID: 10409446)
1. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
Mark HF; Feldman D; Das S; Kye H; Mark S; Sun CL; Samy M
Exp Mol Pathol; 1999 Jun; 66(2):170-8. PubMed ID: 10409446
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
Mark HF; Samy M; Santoro K; Mark S; Feldman D
Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
[TBL] [Abstract][Full Text] [Related]
3. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
5. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
6. Assessment of chromosomal trisomies in prostate cancer using fluorescent in situ hybridization.
Mark HF; Feldman D; Das S; Samy M; Sun CL; Mark S
Exp Mol Pathol; 1999 Oct; 67(2):109-17. PubMed ID: 10527762
[TBL] [Abstract][Full Text] [Related]
7. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
8. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
10. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
11. Additional Her 2/neu gene copies in patients with Sézary syndrome.
Utikal J; Poenitz N; Gratchev A; Klemke CD; Nashan D; Tüting T; Goerdt S
Leuk Res; 2006 Jun; 30(6):755-60. PubMed ID: 16303179
[TBL] [Abstract][Full Text] [Related]
12. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
13. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
14. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko TA; Blackwood MA; Schumm PL; Hagos FG; Adeyanju MO; Feldman MD; Sanders MO; Weber BL; Olopade OI
Cancer Res; 2002 Mar; 62(5):1481-8. PubMed ID: 11888924
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between aneuploidy of chromosome 17 and amplification of HER-2/neu gene in the different histological type of breast cancer].
Kuroso K; Ueda Y; Mori Y
Rinsho Byori; 2004 Nov; 52(11):897-9. PubMed ID: 15658468
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
17. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
[TBL] [Abstract][Full Text] [Related]
18. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
Young SR; Liu WH; Brock JA; Smith ST
Genes Chromosomes Cancer; 1996 Jun; 16(2):130-7. PubMed ID: 8818660
[TBL] [Abstract][Full Text] [Related]
19. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
